Metastases free thyroid cancer patients harbouring mutations may benefit from a more intensive treatment and follow-up.
作者信息
Antonelli Alessandro, Ferrari Silvia Martina, Elia Giusy, Patrizio Armando, Fallahi Poupak
机构信息
Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy.
Department of Translational Research of New Technologies in Medicine and Surgery, University of Pisa, Pisa, Italy.
出版信息
Gland Surg. 2019 Jun;8(3):298-300. doi: 10.21037/gs.2019.05.05.
Abstract
摘要
相似文献
1
Metastases free thyroid cancer patients harbouring mutations may benefit from a more intensive treatment and follow-up.携带突变的无转移甲状腺癌患者可能从更强化的治疗和随访中获益。
Gland Surg. 2019 Jun;8(3):298-300. doi: 10.21037/gs.2019.05.05.
2
TERT promoter mutations identify a high-risk group in metastasis-free advanced thyroid carcinoma.TERT 启动子突变鉴定出无转移的晚期甲状腺癌中的高危人群。
Eur J Cancer. 2019 Feb;108:41-49. doi: 10.1016/j.ejca.2018.12.003. Epub 2019 Jan 12.
3
TERT promoter mutations are associated with distant metastases in papillary thyroid carcinoma.TERT 启动子突变与甲状腺乳头状癌的远处转移有关。
Eur J Endocrinol. 2015 Apr;172(4):403-13. doi: 10.1530/EJE-14-0837. Epub 2015 Jan 12.
4
Highly Concordant Key Genetic Alterations in Primary Tumors and Matched Distant Metastases in Differentiated Thyroid Cancer.分化型甲状腺癌原发肿瘤与配对远处转移灶中高度一致的关键基因改变
Thyroid. 2016 May;26(5):672-82. doi: 10.1089/thy.2015.0527.
5
TERT promoter mutations and long-term survival in patients with thyroid cancer.甲状腺癌患者的端粒酶逆转录酶（TERT）启动子突变与长期生存
Endocr Relat Cancer. 2016 Oct;23(10):813-23. doi: 10.1530/ERC-16-0219. Epub 2016 Aug 15.
6
TERT promoter mutation in primary papillary thyroid carcinoma lesions predicts absent or lower i uptake in metastases.原发性甲状腺乳头状癌病变中的 TERT 启动子突变可预测转移灶中 i 摄取的缺失或降低。
IUBMB Life. 2019 Jul;71(7):1030-1040. doi: 10.1002/iub.2056. Epub 2019 Apr 26.
7
Prognostic effects of TERT promoter mutations are enhanced by coexistence with BRAF or RAS mutations and strengthen the risk prediction by the ATA or TNM staging system in differentiated thyroid cancer patients.TERT 启动子突变的预后影响因与 BRAF 或 RAS 突变共存而增强，并通过 ATA 或 TNM 分期系统加强分化型甲状腺癌患者的风险预测。
Cancer. 2016 May 1;122(9):1370-9. doi: 10.1002/cncr.29934. Epub 2016 Mar 11.
8
TERT, BRAF, and NRAS in Primary Thyroid Cancer and Metastatic Disease.原发性甲状腺癌和转移性疾病中的端粒酶逆转录酶（TERT）、BRAF和NRAS
J Clin Endocrinol Metab. 2017 Jun 1;102(6):1898-1907. doi: 10.1210/jc.2016-2785.
9
TERT promoter mutations in thyroid cancer: a report from a Middle Eastern population.甲状腺癌中的端粒酶逆转录酶（TERT）启动子突变：来自中东人群的报告。
Endocr Relat Cancer. 2015 Dec;22(6):901-8. doi: 10.1530/ERC-15-0396. Epub 2015 Sep 9.
10
Impact of BRAF V600E and TERT Promoter Mutations on Response to Therapy in Papillary Thyroid Cancer.BRAF V600E 和 TERT 启动子突变对甲状腺乳头状癌治疗反应的影响。
Endocrinology. 2019 Oct 1;160(10):2328-2338. doi: 10.1210/en.2019-00315.
引用本文的文献
1
Dabrafenib plus trametinib treatment in patients with anaplastic thyroid carcinoma: an Argentinian experience.达布拉非尼联合曲美替尼治疗间变性甲状腺癌：阿根廷经验。
Endocrine. 2023 Apr;80(1):134-141. doi: 10.1007/s12020-022-03295-2. Epub 2023 Jan 9.
2
Molecular features of aggressive thyroid cancer.侵袭性甲状腺癌的分子特征
Front Oncol. 2022 Dec 20;12:1099280. doi: 10.3389/fonc.2022.1099280. eCollection 2022.
3
Dramatic clinical response to dabrafenib plus trametinib in anaplastic thyroid carcinoma and the challenges faced during the COVID-19 pandemic.达拉非尼联合曲美替尼治疗间变性甲状腺癌的显著临床疗效及 COVID-19 大流行期间面临的挑战。
Arch Endocrinol Metab. 2021 Nov 1;65(2):242-247. doi: 10.20945/2359-3997000000325. Epub 2021 Feb 15.
4
Thyroid Lobectomy for Low to Intermediate Risk Differentiated Thyroid Cancer.甲状腺叶切除术治疗低至中危分化型甲状腺癌。
Cancers (Basel). 2020 Nov 6;12(11):3282. doi: 10.3390/cancers12113282.
5
Novel treatments for anaplastic thyroid carcinoma.间变性甲状腺癌的新型治疗方法。
Gland Surg. 2020 Jan;9(Suppl 1):S28-S42. doi: 10.21037/gs.2019.10.18.
本文引用的文献
1
Genetic-guided Risk Assessment and Management of Thyroid Cancer.遗传指导下的甲状腺癌风险评估与管理。
Endocrinol Metab Clin North Am. 2019 Mar;48(1):109-124. doi: 10.1016/j.ecl.2018.11.007.
2
TERT promoter mutations identify a high-risk group in metastasis-free advanced thyroid carcinoma.TERT 启动子突变鉴定出无转移的晚期甲状腺癌中的高危人群。
Eur J Cancer. 2019 Feb;108:41-49. doi: 10.1016/j.ejca.2018.12.003. Epub 2019 Jan 12.
3
Molecular testing in the diagnosis of differentiated thyroid carcinomas.分子检测在分化型甲状腺癌诊断中的应用
Gland Surg. 2018 Aug;7(Suppl 1):S19-S29. doi: 10.21037/gs.2017.11.07.
4
The role of TERT promoter mutations in postoperative and preoperative diagnosis and prognosis in thyroid cancer.TERT启动子突变在甲状腺癌术后及术前诊断和预后中的作用。
Medicine (Baltimore). 2018 Jul;97(29):e11548. doi: 10.1097/MD.0000000000011548.
5
Prognostic implication of BRAF and TERT promoter mutation combination in papillary thyroid carcinoma-A meta-analysis.甲状腺乳头状癌中 BRAF 和 TERT 启动子突变组合的预后意义：一项荟萃分析。
Clin Endocrinol (Oxf). 2017 Nov;87(5):411-417. doi: 10.1111/cen.13413. Epub 2017 Aug 2.
6
Refining Dynamic Risk Stratification and Prognostic Groups for Differentiated Thyroid Cancer With TERT Promoter Mutations.优化具有TERT启动子突变的分化型甲状腺癌的动态风险分层和预后分组
J Clin Endocrinol Metab. 2017 May 1;102(5):1757-1764. doi: 10.1210/jc.2016-3434.
7
Primary Thyroid Carcinoma with Low-Risk Histology and Distant Metastases: Clinicopathologic and Molecular Characteristics.具有低风险组织学特征和远处转移的原发性甲状腺癌：临床病理及分子特征
Thyroid. 2017 May;27(5):632-640. doi: 10.1089/thy.2016.0582. Epub 2017 Feb 1.
8
2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer.2015年美国甲状腺协会成人甲状腺结节和分化型甲状腺癌管理指南：美国甲状腺协会甲状腺结节和分化型甲状腺癌指南工作组
Thyroid. 2016 Jan;26(1):1-133. doi: 10.1089/thy.2015.0020.
9
Association between BRAF V600E mutation and recurrence of papillary thyroid cancer.BRAF V600E突变与甲状腺乳头状癌复发之间的关联。
J Clin Oncol. 2015 Jan 1;33(1):42-50. doi: 10.1200/JCO.2014.56.8253. Epub 2014 Oct 20.
10
TERT promoter mutations are a major indicator of poor outcome in differentiated thyroid carcinomas.TERT 启动子突变是分化型甲状腺癌不良预后的一个主要指标。
J Clin Endocrinol Metab. 2014 May;99(5):E754-65. doi: 10.1210/jc.2013-3734. Epub 2014 Jan 29.
Zotero 插件